Alto Neuroscience, Inc. (NYSE:ANRO) — Market Cap & Net Worth
Market Cap & Net Worth: Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience, Inc. (NYSE:ANRO) has a market capitalization of $850.38 Million ($850.38 Million) as of September 17, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #9611 globally and #2658 in its home market, demonstrating a -14.91% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alto Neuroscience, Inc.'s stock price $30.25 by its total outstanding shares 35052731 (35.05 Million). Also see ANRO asset base for a full breakdown of the balance sheet.
Alto Neuroscience, Inc. Market Cap History: 2024 to 2026
Alto Neuroscience, Inc.'s market capitalization history from 2024 to 2026. Data shows growth from $146.17 Million to $1.06 Billion (27.50% CAGR). Also see Alto Neuroscience, Inc. cash flow conversion for how efficiently the company converts equity into cash flow.
Alto Neuroscience, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alto Neuroscience, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ANRO stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ANRO by Market Capitalization
Companies near Alto Neuroscience, Inc. in the global market cap rankings as of September 17, 2026. Review tangible net worth ratio of Alto Neuroscience, Inc. to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Alto Neuroscience, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Alto Neuroscience, Inc. Historical Marketcap From 2024 to 2026
Between 2024 and today, Alto Neuroscience, Inc.'s market cap moved from $146.17 Million to $ 1.06 Billion, with a yearly change of 27.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.06 Billion | +69.94% |
| 2025 | $623.94 Million | +326.86% |
| 2024 | $146.17 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Alto Neuroscience, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $850.38 Million USD |
| MoneyControl | $850.38 Million USD |
| MarketWatch | $850.38 Million USD |
| marketcap.company | $850.38 Million USD |
| Reuters | $850.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clini… Read more